Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Zydus Lifesciences Limited ( (IN:ZYDUSLIFE) ) has issued an announcement.
Zydus Lifesciences has signed an exclusive agreement with US-based Myriad Genetics to introduce a suite of advanced cancer-risk assessment and prognostic diagnostic tests in India, including the MyRisk Hereditary Cancer Test, MyChoice HRD Plus for ovarian cancer, and Prolaris for prostate cancer. The collaboration aims to expand access to precision oncology by providing clinicians and patients with more accurate tools to assess hereditary cancer risks, understand tumour biology, predict disease progression and tailor personalised treatment plans, thereby strengthening diagnostic infrastructure, clinician education and potentially improving clinical outcomes for cancer patients across the country.
More about Zydus Lifesciences Limited
Zydus Lifesciences Limited is an innovation-led life sciences company with an international presence, operating in the pharmaceuticals and healthcare sector. The company focuses on patient-centric solutions and precision oncology, offering a range of therapies and now expanding into advanced molecular diagnostic tests to support personalised, evidence-based cancer care in the Indian market.
Average Trading Volume: 28,041
Technical Sentiment Signal: Hold
Current Market Cap: 919.6B INR
See more data about ZYDUSLIFE stock on TipRanks’ Stock Analysis page.